Tokushima University / Educator and Researcher Directory --- Yoshikawa, Masato

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : Value of the fibrinogen-platelet ratio in patients with resectable pancreatic cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 342-346, 2021. (Summary) Background : Several prognostic factors were reported in pancreatic cancer. The fibrinogen-platelet ratio (FPR) was reported as a prognostic factor of resectable gastric cancer. In this report, the FPR was evaluated in patients with resectable pancreatic cancer. Methods : Between 2004 and 2019, 163 patients with curative resection for pancreatic cancer were enrolled. Cases of non-curative resection were excluded. The FPR was calculated using the preoperative plasma fibrinogen and the platelet counts and the cut-off value was determined by receiver operating characteristic (ROC) curve analysis. The patients were divided into high and low FPR groups according to this cut-off value. Results : The cut-off value of FPR was 25.2. Among age, sex, body mass index (BMI), and surgical factors including surgery type, volume of blood loss and surgery time, there was no significant difference between the two groups. Patients in the low FPR group had significantly better overall survival (OS) and relapse-free survival (RFS) compared with the high FPR group (P < 0.05). On multivariate analysis, a high FPR, CA19-9 > 300 U /l, and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. Conclusions : The FPR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 342-346, August, 2021. (Keyword) Biomarkers, Tumor / Fibrinogen / Humans / Neoplasm Recurrence, Local / Pancreatic Neoplasms / Prognosis / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 116535 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.342 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759156 ● Search Scopus @ Elsevier (PMID): 34759156 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.342 (Tokushima University Institutional Repository: 116535, DOI: 10.2152/jmi.68.342, PubMed: 34759156)
2.	Youichiro Kawashita, Yuji Morine, Yu Saitou, Chie Takasu, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, Masato Yoshikawa, Satoru Imura, Toshiyuki Yagi and Mitsuo Shimada : Role of heat shock factor 1 expression in the microenvironment of intrahepatic cholangiocarcinomas., Journal of Gastroenterology and Hepatology, Vol.33, No.7, 1407-1412, 2018. (Summary) Heat shock factor 1 (HSF1), a master regulator of heat shock response, has been shown to play a multifaceted role in cancer progression. However, the clinical significance and biological effect of HSF1 expression in intrahepatic cholangiocarcinoma (IHCC) remain unknown. Forty-nine patients with IHCC who underwent hepatic resection were enrolled in this study. HSF1 expression in tumor tissue was determined by immunohistochemistry, and patients were divided into two groups, those with high (n = 20) and low (n = 29) HSF1 expression. Clinicopathological factors including prognosis were compared in these two groups. HSF1 expression was significantly higher in tumors than in normal tissue. The overall survival rate was significantly lower in patients with high than low HSF1. Multivariate analysis showed that high HSF1 expression was a factor independently prognostic of patient survival. High HSF1 expression in tumor tissues may be a prognostic biomarker in patients with IHCC. (Keyword) Adult / Aged / Aged, 80 and over / Bile Duct Neoplasms / Cell Line, Tumor / Cholangiocarcinoma / Disease Progression / Female / Gene Expression / Heat Shock Transcription Factors / Humans / Immunohistochemistry / Male / Middle Aged / Multivariate Analysis / Prognosis / Survival Rate / Tumor Microenvironment (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.14078 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29278438 ● Summary page in Scopus @ Elsevier: 2-s2.0-85043330492 (DOI: 10.1111/jgh.14078, PubMed: 29278438, Elsevier: Scopus)
3.	Satoru Imura, Hiroki Teraoku, Masato Yoshikawa, Daichi Ishikawa, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Potential predictive factors for microvascular invasion in hepatocellular carcinoma classified within the Milan criteria., International Journal of Clinical Oncology, Vol.23, No.1, 98-103, 2018. (Summary) Microvascular invasion (mvi) is an important risk factor for recurrent hepatocellular carcinoma (HCC), even after curative liver resection or orthotopic liver transplantation. However, mvi is difficult to detect preoperatively. The aim of this study was to clarify the risk factors of postoperative recurrence and investigate predictive factors of mvi before hepatectomy for HCC classified within the Milan criteria. One hundred fifty-nine patients with hepatocellular carcinoma (HCC) classified within the Milan criteria, who underwent hepatectomy, were enrolled in this study. We investigated the risk factors of recurrence. In addition, we divided them into two groups: mvi-negative group and mvi-positive group, based on pathological findings after surgery. We compared the clinicopathological factors between the two groups and determined the risk factors for mvi. Overall survival rate at 1, 3, and 5 years were 91.6%, 80.5%, and 74.9%, and the recurrence-free survival rate at 1, 3, and 5-years were 72.3%, 51.6%, and 37.2%. Risk factor analysis for tumor recurrence revealed that total bilirubin, albumin, ICGR15, AFP-L3, tumor number, mvi, and tumor stage had a significant predictive value. Multivariate analysis revealed that tumor number and mvi were significant independent risk factors for tumor recurrence. Predictive analysis for risk factors of mvi revealed that multiple tumors and AFP-L3 > 10% were significant independent risk factors for mvi in HCC classified within the Milan criteria. The mvi was one of the independent risk factors for tumor recurrence in HCC classified within the Milan criteria. Multiple tumors and high AFP-L3 value were independent predictive factors for mvi. (Keyword) Aged / Bilirubin / Carcinoma, Hepatocellular / Disease-Free Survival / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Neoplasm Recurrence, Local / Retrospective Studies / Risk Factors / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-017-1189-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28875240 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028981662 (DOI: 10.1007/s10147-017-1189-8, PubMed: 28875240, Elsevier: Scopus)

Academic Paper (Unrefereed Paper):

1.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of Frailty in Prognosis After Hepatectomy for Elderly Patients with Hepatocellular Carcinoma., Annals of Surgical Oncology, Vol.28, No.1, 439-446, 2021. (Summary) The concept of frailty becomes important for patients who undergo surgery in this recent aging society. The aim of this study is to investigate the frailty as a prognostic factor in elderly patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. A total of 92 patients over 75 years old who underwent hepatectomy were enrolled in this study. Frailty was defined as clinical frailty scale (CFS) 4. Patients were divided into two groups, i.e., frailty group (n = 21) and no-frailty group (n = 71), and clinicopathological features were compared between them. The frailty group showed significant higher PIVKA-II level and larger tumor diameter (p < 0.05). CRP level and modified Glasgow prognostic score were significantly higher in the frailty group (p < 0.05). The frailty group showed higher rate of postoperative complications of Clavien-Dindo III (p = 0.06) and longer postoperative stay (p = 0.08). Cancer-specific, overall, and disease-free survival rates were significantly worse in the frailty group (p < 0.05). Frailty was detected as an independent prognostic factor on multivariate analysis of cancer-specific survival. Frailty can estimate the prognosis of HCC patients who underwent hepatectomy. (Keyword) Aged / Carcinoma, Hepatocellular / Frail Elderly / Frailty / Hepatectomy / Humans / Liver Neoplasms / Neoplasm Recurrence, Local / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-020-08742-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32562115 ● Search Scopus @ Elsevier (PMID): 32562115 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-020-08742-w (DOI: 10.1245/s10434-020-08742-w, PubMed: 32562115)
2.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : Value of the CRP-albumin ratio in patients with resectable pancreatic cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 244-255, 2021. (Summary) Background : The C-reactive protein (CRP)-albumin ratio (CAR) was reported as a prognostic factor of resectable hepatocellular carcinoma. The aim of this study was to analyse the significance of CAR in resectable pancreatic cancer. Patients and Methods : 163 patients with curative resection for pancreatic cancer were enrolled in this retrospective study. Cases of non-curative resection were excluded. The CAR was calculated with the preoperative plasma CRP and albumin values, with a cut-off value of 0.06, as calculated in a previous report. Results : Patients in the low CAR group had significantly better overall survival (OS) and disease-free survival (DFS) compared with the high CAR group (P < 0.05). On multivariate analysis, for high CAR, CA19-9 > 300 U /l and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. High CAR was significantly associated with advanced T stage. Conclusion : The CAR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 244-248, August, 2021. (Keyword) Albumins / C-Reactive Protein / Humans / Pancreatic Neoplasms / Prognosis / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 116489 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.244 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759138 ● Search Scopus @ Elsevier (PMID): 34759138 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.244 (Tokushima University Institutional Repository: 116489, DOI: 10.2152/jmi.68.244, PubMed: 34759138)
3.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : Prognostic prediction of apparent diffusion coefficient obtained by diffusion-weighted MRI in mass-forming intrahepatic cholangiocarcinoma., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.27, No.7, 388-395, 2020. (Summary) We evaluated apparent diffusion coefficient (ADC) of diffusion-weighted image MRI as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma (IHCC). We enrolled 26 patients who had undergone hepatic resections for mass-forming-type IHCC in this study, and calculated their mean ADC, using diffusion-weighted image MRI (b: 0, 20, 800 seconds/mm ; 1.5 T MRI). Patients were divided into the ADC and the ADC groups at the median ADC value (n = 13 for both). We also immunohistochemically evaluated hypoxia-inducible factor (HIF)-1 in tumor tissue. Median age in the ADC was older (P = .03), and showed significant higher rate of scirrhous tumor (P = .02). The 5-year overall survival rate in the ADC group was significantly worse than in the ADC group (P = .04). In multivariate analysis, hilar tumor, portal vein invasion and low ADC were independent prognostic factors (P < .05). The ADC group also had a higher rate of high HIF-1 expression than the ADC group (P < .05). Representative case of ADC group showed rich stroma and high HIF-1 expression. The ADC values in MRIs can predict IHCC prognosis, and correlated with stromal density and HIF-1 expression. (Keyword) Aged / Algorithms / Bile Duct Neoplasms / Biomarkers, Tumor / Cholangiocarcinoma / Contrast Media / Diffusion Magnetic Resonance Imaging / Female / Hepatectomy / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Male / Neoplasm Invasiveness / Prognosis / Survival Rate / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1002/jhbp.732 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32162483 ● Search Scopus @ Elsevier (PMID): 32162483 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.732 (DOI: 10.1002/jhbp.732, PubMed: 32162483)
4.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging., PLoS ONE, Vol.14, No.1, e0210579, 2019. (Summary) Dynamic magnetic resonance imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (EOB-MRI) can be used not only to detect liver tumors but also to estimate liver function. The aim of this study was to establish a new EOB-MRI-based formula to determine the resection limit in patients undergoing hepatectomy. Twenty-eight patients with a normal liver (NL group) and five with an unresectable cirrhotic liver (UL group) who underwent EOB-MRI were included. Standardized liver function (SLF) was calculated based on the signal intensity (SI), the volume of each subsegment (S1-S8), and body surface area. A formula defining the resection limit was devised based on the difference in the SLF values of patients in the NL and UL groups. The formula was validated in 50 patients who underwent EOB-MRI and hepatectomy. The average SLF value in the NL and UL groups was 2038 and 962 FV/m2, respectively. The difference (1076 FV/m2) was consistent with a 70% in resection volume. Thus, the resection limit for hepatectomy was calculated as a proportion of 70%: 70 (SLF-962)/1076 (%). The one patient who underwent hepatectomy over the resection limit died due to liver failure. In other 49 patients, in whom the resection volume was less than the resection limit, procedures were safely performed. Our formula for resection limit based on EOB-MRI can improve the safety of hepatectomy. (Tokushima University Institutional Repository) ● Metadata: 113041 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0210579 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30682046 ● Search Scopus @ Elsevier (PMID): 30682046 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0210579 (Tokushima University Institutional Repository: 113041, DOI: 10.1371/journal.pone.0210579, PubMed: 30682046)
5.	Toshiaki Yoshimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa, Jun Higashijima, Chie Takasu and Mitsuo Shimada : Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases., In Vivo, Vol.31, No.3, 419-423, 2017. (Summary) Surgical resection is currently considered the only potentially curative option as a treatment strategy of colorectal liver metastases (CRLM). However, the criteria for selection of resectable CRLM are not clear. The aim of this study was to confirm a new prognostic indicator of CRLM after hepatic resection. One hundred thirty nine patients who underwent initial surgical resection from 1994 to 2015 were investigated retrospectively. Prognostic factors of overall survival including the product of maximum diameter and number of metastases (MDN) were analyzed. Primary tumor differentiation, vessel invasion, lymph node (LN) metastasis, non-optimally resectable metastases, H score, grade of liver metastases, resection with non-curative intent and MDN were found to be prognostic factors of overall survival (OS). In multivariate analyses of clinicopathological features associated with OS, MDN and non-curative intent were independent prognostic factors. Patients with MDN ·30 had shown significantly poorer prognosis than patients with MDN <30 in OS and relapse-free survival (RFS). MDN ·30 is an independent prognostic factor of survival in patients with CRLM and optimal surgical criterion of hepatectomy for CRLM. (Keyword) Adult / Aged / Aged, 80 and over / Cell Differentiation / Colorectal Neoplasms / Female / Follow-Up Studies / Hepatectomy / Humans / Liver Neoplasms / Lymphatic Metastasis / Male / Middle Aged / Multivariate Analysis / Prognosis / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11076 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28438872 ● Search Scopus @ Elsevier (PMID): 28438872 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.11076 (DOI: 10.21873/invivo.11076, PubMed: 28438872)
6.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition., Anticancer Research, Vol.37, No.3, 1169-1175, 2017. (Summary) Serum carcinoembryonic antigen (CEA) is used as an indicator of tumor progression in a variety of carcinomas. A subset of patients with hepatocellular carcinoma (HCC) exhibit increased serum CEA level, but the significance of this is unclear. In this study, we investigated the prognosis of patients with HCC with increased serum CEA, and explored the correlations with expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and epithelial-mesenchymal transition (EMT) and tumor angiogenesis. One hundred and twenty-three patients with HCC who underwent radical resection were divided into two groups according to a cut-off value of 5.0 ng/ml for serum CEA: high (n=24) and normal (n=99) groups. We compared the clinicopathological factors with serum CEA levels and its correlations with CEACAM1 expression, EMT-related factors and microvessel density (MVD) of tumor tissues by immunohistochemistry. In the high CEA group, the disease-free survival (DFS) rate was significantly worse than in the normal CEA group. Multivariate analysis revealed that a high CEA level was an independent factor predictive of recurrence. Furthermore, increased serum CEA levels were positively correlated with CEACAM1 expression. Moreover, CEACAM1 expression was positively correlated with expression of EMT-related factors and MVD of tumor tissues. Increased serum CEA level reflected CEACAM1 expression and was an independent factor predictive of recurrence in HCC through EMT and tumor angiogenesis. (Keyword) Adult / Aged / Aged, 80 and over / Antigens, CD / Antigens, CD34 / Cadherins / Carcinoembryonic Antigen / Carcinoma, Hepatocellular / Cell Adhesion Molecules / Disease-Free Survival / Epithelial-Mesenchymal Transition / Female / Follow-Up Studies / Humans / Immunohistochemistry / Liver Neoplasms / Male / Microcirculation / Middle Aged / Neovascularization, Pathologic / Predictive Value of Tests / Preoperative Period / Prognosis / Recurrence / Vimentin (Tokushima University Institutional Repository) ● Metadata: 112034 (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.11430 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28314278 ● Search Scopus @ Elsevier (PMID): 28314278 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.11430 (Tokushima University Institutional Repository: 112034, DOI: 10.21873/anticanres.11430, PubMed: 28314278)
7.	M Davaadorj, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Chie Takasu, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa and Mitsuo Shimada : Loss of Secreted Frizzled-Related Protein-1 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma., EJSO - European Journal of Surgical Oncology, Vol.43, No.2, 344-350, 2017. (Summary) Secreted Frizzled-Related Protein-1 (SFRP1) is a well-known negative regulator of the wingless type (Wnt)- -catenin pathway and its inactivation plays an important role in the development and progression of many cancers. In this study, we aimed to determine the clinical significance of SFRP1 expression in intrahepatic cholangiocarcinoma (IHCC) and to define the relationship to Wnt- -catenin pathway. Fifty IHCC patients who had liver resection were enrolled in this study. SFRP1 protein expression was examined by immunohistochemistry in tumor tissues. The patients were divided into two groups: SFRP1 positive (n = 30) and negative (n = 20). Clinicopathological characteristics were analyzed. SFRP1 significantly correlated with curability (Cur A, B vs. C, p = 0.029); and recurrent pattern (intrahepatic vs. extrahepatic, p = 0.010). The negative SFRP1 group had significantly poorer prognosis, and 5-year survival rates were 8.1% of the negative SFRP1 group and 44.6% of the positive SFRP1 group, respectively. Moreover, the disease-free survival rate in the negative SFRP1 group was significantly poorer (p < 0.001). Multivariate analysis revealed that loss of SFRP1served as an independent prognostic factor in IHCC for both overall (HR, 2.923; 95% CI, 1.30-6.56; p = 0.009) and disease-free (HR, 2.631; 95% CI, 1.31-5.27; p = 0.006) survival. In addition, SFRP1 expression negatively correlated to -catenin expression (p = 0.005). Those results suggested that the loss of SFRP1 could be a poor prognostic factor for IHCC, through the Wnt- -catenin pathway. (Keyword) Aged / Biomarkers, Tumor / Cholangiocarcinoma / Female / Hepatectomy / Humans / Immunohistochemistry / Japan / Liver Neoplasms / Male / Prognosis / Proteins / Survival Rate (Tokushima University Institutional Repository) ● Metadata: 110034 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejso.2016.11.017 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28062160 ● Search Scopus @ Elsevier (PMID): 28062160 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejso.2016.11.017 (Tokushima University Institutional Repository: 110034, DOI: 10.1016/j.ejso.2016.11.017, PubMed: 28062160)

Review, Commentary:

1.	Shin-ichiro Yamada, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : Effective stepwise training and procedure standardization for young surgeons to perform laparoscopic left hepatectomy., Surgical Endoscopy, Vol.31, No.6, 2623-2629, Dec. 2016. (Summary) Laparoscopic hepatectomy remains one of the most difficult procedures for young surgeons to perform. We recently developed a new training method and standardization procedure for teaching young surgeons to perform laparoscopic left hepatectomy (Lap-LHx). The aim of this study was to assess the effectiveness of our method. In 2004, we standardized a laparoscopic procedure for Lap-LHx, using a laparoscopy-assisted method as a stepping stone. The laparoscopic training method comprised the following three steps: (1) training in fundamental procedures using a dry box and checking by mentors; (2) detailed preoperative simulation using Vincent three-dimensional software for each patient; and (3) self-assessment including understanding of relevant anatomy and completion grade for each procedure using a check sheet and feedback by both mentors and a professor. Twenty-three Lap-LHx procedures performed during the study period were divided into two groups: those performed by young non-board-certified surgeons (n = 9) and those performed by senior board-certified surgeons (n = 14). The blood loss and operative time were similar in the young surgeon (194 g and 336 min, respectively) and senior surgeon groups (208 g and 322 min, respectively). Our standardized Lap-LHx procedure and stepwise training to perform it enable young surgeons to perform Lap-LHx as confidently and safely as more experienced surgeons. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-016-5273-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27928671 ● Search Scopus @ Elsevier (PMID): 27928671 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-016-5273-3 (DOI: 10.1007/s00464-016-5273-3, PubMed: 27928671)
2.	Shinichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku and Mitsuo Shimada : Liver regeneration after splenectomy in patients with liver cirrhosis., Hepatology Research, Vol.46, No.5, 443-449, Oct. 2016. (Summary) Splenectomy is a well-known procedure to improve thrombocytopenia and liver function in patients with liver cirrhosis (LC). However, the effect of splenectomy on liver regeneration remains unclear. The aim of this study is to investigate the effect of splenectomy on liver regeneration. Twenty patients with LC who underwent splenectomy were included in this study. Liver and splenic volumes were measured by a 3-D simulation imaging system. Liver volume (LV) and clinicopathological data were compared before and 6 months after splenectomy. Thereafter, patients were divided into two groups: the elevated LV group and the reduced LV group. Patient characteristics were compared between the two groups. Postoperative LV was increased in 14 patients compared with the preoperative state. Thrombocytopenia, leukopenia, total bilirubin and prothrombin time were improved after splenectomy. In the elevated LV group, four patients exhibited improved Child-Pugh grades after splenectomy, whereas no patients demonstrated improvement in the reduced LV group. The elevated LV group exhibited high albumin level, good indocyanine green retention rate at 15 min and large splenic volume compared with the same measurements in the decreased group. Patients with larger spleen volumes and higher albumin values before splenectomy showed increased rates of LV after splenectomy. Splenectomy for patients with LC improved pancytopenia and liver function. Especially, in patients with large spleen and high albumin levels, considerable increases in LV and improved liver function were observed. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.12573 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26428414 ● Search Scopus @ Elsevier (PMID): 26428414 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.12573 (DOI: 10.1111/hepr.12573, PubMed: 26428414)

Proceeding of International Conference:

1.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of frailty in prognosis after hepatectomy in older patients with hepatocellular carcinoma., ASCO-GI, San Francisco, Jan. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-020-08742-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32562115 ● Search Scopus @ Elsevier (PMID): 32562115 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-020-08742-w (DOI: 10.1245/s10434-020-08742-w, PubMed: 32562115)
2.	Yusuke Arakawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Evaluation of the ratio of plasma fibrinogen to platelet in resectable pancreatic cancer., ASCO-GI, San Francisco, Jan. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2020.38.4_suppl.756 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2020.38.4_suppl.756 (DOI: 10.1200/JCO.2020.38.4_suppl.756)
3.	Masato Yoshikawa, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou and Katsuki Miyazaki : Prognostic prediction of mass-forming intrahepatic cholangiocarcinoma from ADC value of DWI-MRI, IASGO2019, Bangkok, Oct. 2019.
4.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : Preoperative Prognostic Nutritional Index Predicts Both Short-and Long-Term Outcomes after Liver Resection For Hepatocellular Carcinoma, AMERICAN COLLEGE OF SURGEONS 2017(ACS), San Diego, Oct. 2017.
5.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Masato Yoshikawa : Reduced-port laparoscopic cholecystectomy with 3mm minute-diameter forceps., SAGES, Houston, Mar. 2017.
6.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Comparative analysis of the outcome between open and laparoscopic partial liver resection for hepatocellular carcinoma., SAGES, Houston, Mar. 2017.
7.	Mitsuo Shimada, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Jun Higashijima : New technology of `One-stop shop' liver surgery simulation equipped with assessment of total and regional liver functional reserve., SAGES, Houston, Mar. 2017.
8.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa and Jun Higashijima : Treatment strategy for colorectal liver metastases:Clinical impact of FOLFOXIRI regimen for unresectable cases., ASCO-GI, San Francisco, Jan. 2017. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2017.35.4_suppl.780 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2017.35.4_suppl.780 (DOI: 10.1200/JCO.2017.35.4_suppl.780)
9.	Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku and Jun Higashijima : Characteristics of intrahepatic cholangiocarcinoma according to tumor location., ASCO-GI, San Francisco, Jan. 2017. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2017.35.4_suppl.406 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2017.35.4_suppl.406 (DOI: 10.1200/JCO.2017.35.4_suppl.406)
10.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : Current status and effect of laparoscopic training for young surgeon, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
11.	Daichi Ishikawa, Tetsuya Ikemoto, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Yuji Morine, Satoru Imura and Mitsuo Shimada : Signigficance of CD4+CD49b+regulatory T cells and Foxp3+regulatory T cells in the peripheral blood of cancer patients, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
12.	Atsushi Takata, Jun Higashijima, Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Hideya Kashihara, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : The influence of circular muscle incision on intestinal peristalsis and anastomosis, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
13.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : Recurrent feature after radiofrequency ablation therapy for hepatocellular carcinoma, 4th International Conference of FACO, 廈門, Sep. 2016.
14.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : Elevated preoperative serum CEA levels in patients with HCC is associated with prognosis and EMT, 26th World Congress Of the IASGO 2016, Seoul, Sep. 2016.
15.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : Elevated preoperative serum CEA levels in patients with HCC is associated with prognosis and EMT, 第8回日本・モンゴル消化器癌国際シンポジウム, ウランバートル, Aug. 2016.
16.	Satoru Imura, Masato Yoshikawa, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Our strategy for antibody mediated rejection in living donor liver transplantation, 第8回日本・モンゴル消化器癌国際シンポジウム, ウランバートル, Aug. 2016.
17.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : The effect od HDACi in ADSC differentiation in to insulin producing cells., Transplantation Science Symposium (TSS) Asian Regional Meeting 2016, Tokyo, Apr. 2016.
18.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Hiroki Teraoku : Treatment strategy for intrahepatic cholangiocarcinoma: From optimal surgical management to adjuvant therapy., 2016 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2016.

Proceeding of Domestic Conference:

1.	Hiroyuki Sumitomo, Yukikiyo Kawakami, 富永景子, Masato Yoshikawa, 石橋佳奈, 梅田穂奈美, Takuya Tokunaga, 山崎誠司, Tsutomu Ando and Hiromitsu Takizawa : ラッププロテクターとストーマパウチを用いた簡易開窓術が症状緩和に有効であった肺癌終末期膿胸の1例, 第86回日本臨床外科学会学術集会, Nov. 2024.
2.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of frailty for elderly patients in HPB surgery, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
3.	Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, Maki Sugimoto and Mitsuo Shimada : Intraoperative support with 3D holographic cholangiography and indocyanine green navigation, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
4.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : The impact of frailty as a prognostic factor of colorectal liver metastasis, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
5.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : The value of CRP albumin ratio in patient with resectable pancreas cancer, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
6.	Tetsuya Ikemoto, Kazunori Tokuda, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Basic research for aiming non-clinical PoC acquisition of insulin producing cells from ADSC with Tokushima protocol, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
7.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : Optimal surgical treatment including lymph nodes dissection and adjuvant chemotherapy for intrahepatic cholangiocarcinoma, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
8.	Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Standardization and stepwise training for safe laparoscopic hepatectomy, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
9.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Kazunori Tokuda and Katsuki Miyazaki : 肝胆膵領域悪性腫瘍におけるNrf2・VEGFに着目した腫瘍関連マクロファージ活性化についての検討, 第29回日本癌病態治療研究, Jan. 2021.
10.	Yu Saitou, 高露萍, Tetsuya Ikemoto, Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への3次元分化誘導, 第38回日本肝移植学会学術集, Dec. 2020.
11.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, 杉本真樹 and Mitsuo Shimada : Hologramを用いた術中手術支援-術中Real-time3D胆管造影を併用した胆道手術-, 第45回日本外科系連合学会学術集会, Dec. 2020.
12.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第56回日本肝癌研究会, Dec. 2020.
13.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第56回日本肝癌研究会, Dec. 2020.
14.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : 大腸癌同時性肝転移に対する治療戦略-肝切除適応基準とConversion Surgery-, 第56回日本肝癌研究会, Dec. 2020.
15.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Toshiaki Yoshimoto and Yukako Takehara : ロボット支援下胃癌手術におけるLeft handed LCS techniqueの有用性, 第75回日本消化器外科学会総会, Dec. 2020.
16.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Toshiaki Yoshimoto and Yukako Takehara : TpTMEにおける前壁側剥離の工夫 ∼術中尿道造影の有用性∼, 第75回日本消化器外科学会総会, Dec. 2020.
17.	Toshiaki Yoshimoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, Yukako Takehara and Mitsuo Shimada : 膵切除周術期における栄養指標からみた人工膵臓の有用性, 第75回日本消化器外科学会総会, Dec. 2020.
18.	Masato Yoshikawa, Yuji Morine, Shin-ichiro Yamada, Katsuki Miyazaki, Kazunori Tokuda, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : DWI-MRIのADC値を用いた転移性肝癌の切除後予後予測，抗癌剤効果予測に関する検討, 第75回日本消化器外科学会総会, Dec. 2020.
19.	Kazunori Tokuda, Yuji Morine, Shin-ichiro Yamada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 転移性肝癌切除症例におけるFrailの重要性についての検討, 第75回日本消化器外科学会総会, Dec. 2020.
20.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 胆嚢癌の悪性度評価におけるADCの有用性に関する検討, 第75回日本消化器外科学会総会, Dec. 2020.
21.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第75回日本消化器外科学会総会, Dec. 2020.
22.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 当院の肝胆膵手術症例におけるSSIサーベイランスによる検討, 第75回日本消化器外科学会総会, Dec. 2020.
23.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : 長期予後と患者QoLに着目した膵全摘症例の検討, 第75回日本消化器外科学会総会, Dec. 2020.
24.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : 大腸癌同時性肝転移に対する治療戦略-肝切除適応基準とConversion Surgery-, 第75回日本消化器外科学会総会, Dec. 2020.
25.	Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 腹腔鏡下肝左葉切除の標準化への取り組み ∼手技定型化とstepwise training∼, 第75回日本消化器外科学会総会, Dec. 2020.
26.	Katsuki Miyazaki, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 膵頭十二指腸切除術(PD)術後合併症回避に向けた腹腔動脈起始部圧迫症候群の周術期管理, 第56回日本腹部救急医学会総会, Oct. 2020.
27.	Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのLymphocyte / CRP ratio (LCR)の意義, 第120回日本外科学会定期学術集会, Aug. 2020.
28.	Masato Yoshikawa, Yuji Morine, Shin-ichiro Yamada, Katsuki Miyazaki, Kazunori Tokuda, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : DWI-MRIのADC値を用いた転移性肝癌の予後予測に関する検討, 第120回日本外科学会定期学術集会, Aug. 2020.
29.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 膵癌術後予後予測因子としての術前fibrinogen:血小板比の有用性, 第120回日本外科学会定期学術集会, Aug. 2020.
30.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 切除可能大腸癌限局性肝転移の治療指針, 第120回日本外科学会定期学術集会, Aug. 2020.
31.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda and Masato Yoshikawa : 外科医の視点から開発された皮下脂肪から分離した脂肪由来幹細胞のインスリン産生細胞移植に関する研究, 第120回日本外科学会定期学術集会, Aug. 2020.
32.	Kazunori Tokuda, Tetsuya Ikemoto, 高露萍, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 肪由来幹細胞(ADSC)から肝細胞様細胞(HLC)への分化誘導における3D培養の有用性, 第120回日本外科学会定期学術集会, Aug. 2020.
33.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 膵癌切除症例におけるFrailの意義に関する検討, 第120回日本外科学会定期学術集会, Aug. 2020.
34.	Yu Saitou, Mitsuo Shimada, 杉本真樹, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Holographyを用いた次世代術中手術支援とICG蛍光法による肝離断navigation, 第120回日本外科学会定期学術集会, Aug. 2020.
35.	Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 小型肝癌に対する肝実質温存肝区画切除は妥当である, 第120回日本外科学会定期学術集会, Aug. 2020.
36.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのLymphocyte/CRP ratio(LCR)の意義, 第113回日本消化器病学会四国支部例会, Jun. 2020.
37.	Kazunori Tokuda, Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Masato Yoshikawa, Shin-ichiro Yamada, Yusuke Arakawa, Satoru Imura and Yuji Morine : 亜鉛イオンに着目したADSCから製造したInsulin-producing cell 成熟度に関する検討, 第19回日本再生医療学会総会, May 2020.
38.	Tetsuya Ikemoto, Mitsuo Shimada, Kazunori Tokuda, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki, Shin-ichiro Yamada, Yusuke Arakawa, Satoru Imura and Yuji Morine : T1DM患者から採取された脂肪組織から分離したADSCから製造したInsulin-producing cellに関する検討, 第19回日本再生医療学会総会, May 2020.
39.	Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのLymphocyte / CRP ratio (LCR)の意義, 第53回制癌剤適応研究会, Feb. 2020.
40.	Masato Yoshikawa, Shin-ichiro Yamada, Yuji Morine, Katsuki Miyazaki, Kazunori Tokuda, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 転移性肝癌におけるDWI-MRIのADC値を用いた予後予測に関する検討, 第53回制癌剤適応研究会, Feb. 2020.
41.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 腫瘍関連マクロファージを介した肝胆膵癌の悪性度獲得に関する検討, 第53回制癌剤適応研究会, Feb. 2020.
42.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : NBNC肝細胞癌の発癌と進展の分子標的からみた治療戦略, 第53回制癌剤適応研究会, Feb. 2020.
43.	Masato Yoshikawa, Tetsuya Ikemoto, Toshiaki Yoshimoto, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : 膵切除周術期における人工膵臓を用いた血糖管理の有用性, 第260回徳島医学学会学術集会, Feb. 2020.
44.	Masato Yoshikawa, Tetsuya Ikemoto, Toshiaki Yoshimoto, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : 膵切除周術期における人工膵臓を用いた血糖管理の有用性, 第81回日本臨床外科学会総会, Nov. 2019.
45.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Masato Yoshikawa and 杉本真樹 : ホログラムとウェアラブル近赤外蛍光法による肝切除手術支援, 第81回日本臨床外科学会総会, Nov. 2019.
46.	Tetsuya Ikemoto, Kazunori Tokuda, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : insulin-producing cell移植の細胞移植治療への臨床応用に向けた研究, 第81回日本臨床外科学会総会, Nov. 2019.
47.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第81回日本臨床外科学会総会, Nov. 2019.
48.	Yuji Morine, Shin-ichiro Yamada, Tetsuya Ikemoto, Yu Saitou, Yusuke Arakawa, Masato Yoshikawa, Satoru Imura and Mitsuo Shimada : 腸管Microbiome解析を加えた大建中湯の消化器疾患に対する多面的効果の検討, 第81回日本臨床外科学会総会, Nov. 2019.
49.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto, Katsuki Miyazaki and Mitsuo Shimada : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第57回日本癌治療学会学術集会, Oct. 2019.
50.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Mitsuo Shimada : 臨床病理学的特徴と腫瘍悪性度解析からみたNBNC肝細胞癌の治療戦略, 第57回日本癌治療学会学術集会, Oct. 2019.
51.	Masato Yoshikawa, Yu Saitou, 高露萍, Tetsuya Ikemoto, Yusuke Arakawa, Katsuki Miyazaki, Satoru Imura, Yuji Morine and Mitsuo Shimada : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への分化誘導, 第55回日本移植学会総会, Oct. 2019.
52.	Yu Saitou, Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 脳死肝移植ドナー不足解消にむけての取り組み- 医療系学生に対するDonor Action(命の授業)の必要性 –, 第55回日本移植学会総会, Oct. 2019.
53.	Yusuke Arakawa, Yu Saitou, 高露萍, Tetsuya Ikemoto, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞からインスリン産生細胞への分化誘導における赤色LEDの有用性に関する研究, 第55回日本移植学会総会, Oct. 2019.
54.	Tetsuya Ikemoto, Yu Saitou, Satoru Imura, Yuji Morine, Kazunori Tokuda, Shin-ichiro Yamada, Masato Yoshikawa and Mitsuo Shimada : 再生医療技術を用いたinsulin-producing cell移植の臨床応用に向けた研究, 第55回日本移植学会総会, Oct. 2019.
55.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第55回日本胆道学会学術集会, Oct. 2019.
56.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Prognostic prediction of mass-forming intrahepatic cholangiocarcinoma from ADC value of DWI-MRI, JSH International Liver Conference, Oct. 2019.
57.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第78回日本癌学会学術総会, Sep. 2019.
58.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, 杉本真樹 and Mitsuo Shimada : Hologramを用いた次世代術前術中手術支援とICG蛍光法による肝離断navigation, 第14回肝癌治療ナビゲーション研究会, Sep. 2019.
59.	Masato Yoshikawa, Shoko Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, Koichi Tsuneyama and Mitsuo Shimada : 卵巣様間質を伴う非粘液性嚢胞腺腫の二例, 第71回日本消化器画像診断研究会, Sep. 2019.
60.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第71回日本消化器画像診断研究会, Sep. 2019.
61.	Yu Saitou, Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 脳死肝移植ドナー不足解消にむけての取り組み- 医療系学生に対するDonor Action(命の授業)の必要性-, 第37回日本肝移植学会, Jul. 2019.
62.	Yusuke Arakawa, Yu Saitou, 高露萍, Tetsuya Ikemoto, Katsuki Miyazaki, Masato Yoshikawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への分化誘導, 第37回日本肝移植学会, Jul. 2019.
63.	Masato Yoshikawa, Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Shoko Iwahashi and Mitsuo Shimada : 脂肪由来幹細胞からのインスリン産生細胞分化誘導に関する研究, 第26回外科侵襲とサイトカイン研究会, Jul. 2019.
64.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : DWI-MRIのADC値を用いたSorafenibの効果予測に関する検討, 第20回日本肝がん分子標的治療研究会, Jun. 2019.
65.	Chie Takasu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, 市井啓仁 and Mitsuo Shimada : 転写因子制御による肝虚血再灌流障害の新たな治療法の開発, 第255回徳島医学会学術集会, Aug. 2017.
66.	Yu Saitou, Mitsuo Shimada, 瓜生原葉子, Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Shuichi Iwahashi, Tetsuya Ikemoto and Yuji Morine : 脳死肝移植を推進するための学生に対するDonor Actionの必要性について, 第72回日本消化器外科学会総会, Jul. 2017.
67.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : One stop shopを目指したEOB-MRIによる部分肝機能評価, 第72回日本消化器外科学会総会, Jul. 2017.
68.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Jun Higashijima : 大腸癌肝転移に切除基準と腫瘍悪性度評価, 第72回日本消化器外科学会総会, Jul. 2017.
69.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Masato Yoshikawa : 肝胆膵手術における人工膵臓血糖管理の有用性に関する検討, 第72回日本消化器外科学会総会, Jul. 2017.
70.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Hiroki Teraoku : 肝内胆管癌における局在・浸潤形式別悪性度, 第72回日本消化器外科学会総会, Jul. 2017.
71.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 高度門脈侵襲陽性肝癌に対する集学的治療戦略, 第72回日本消化器外科学会総会, Jul. 2017.
72.	Yu Saitou, Hisami Okumura, Yuji Morine, 平山明由, Toshiaki Yoshimoto, Masato Yoshikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : メタボローム解析を用いた肝切除後代謝物解析と肝再生因子の解明, 日本外科代謝栄養学会第54回学術集会, Jul. 2017.
73.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto, Atsushi Takata and Koichi Tsuneyama : 症例, 第53回日本肝癌研究会, Jul. 2017.
74.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : 術前Prognostic nutritional index(PNI)は肝癌術後短期・長期予後予測因子になる, 第53回日本肝癌研究会, Jul. 2017.
75.	Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : ntermediate stage肝癌に対する肝切除の有用性, 第53回日本肝癌研究会, Jul. 2017.
76.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Masato Yoshikawa : NBNC肝細胞癌における臨床病理学的・分子生物学的特徴の解析, 第53回日本肝癌研究会, Jul. 2017.
77.	Shoko Iwahashi, Tetsuya Ikemoto, Mitsuo Shimada, Masato Yoshikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Satoru Imura, Yuji Morine and Koichi Tsuneyama : 単純性嚢胞との鑑別に苦慮した極めて稀な膵嚢胞の1例, 第42回日本外科系連合学会学術集会, Jun. 2017.
78.	Tetsuya Ikemoto, Mitsuo Shimada, Shinsuke Katoh, Masato Yoshikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : 徳島大学病院GRMからみた手術室安全管理の取り組み, 第42回日本外科系連合学会学術集会, Jun. 2017.
79.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Mitsuo Shimada : Treatment outcome for recurrent pancreatic cancer, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
80.	Shuichi Iwahashi, AHMAD AMMAR GHAIBEH, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Hiroki Teraoku : Predictability of postoperative recurrence on hepatocellular carcinoma through the alternating decision tree, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
81.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Masato Yoshikawa : EOB-MRI is useful for `one stop shop` modality based on functional liver volume, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
82.	Masato Yoshikawa, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : Stylization of laparoscopic surgery using 3D simulation for young surgeo, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
83.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Masato Yoshikawa, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : Tr1 cells and Foxp3+regulatory T cell as a diagnostic biomarker for reflecting pathological agressiveness of cystic neoplasm of pancreas, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
84.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Hiroki Teraoku : Treatment strategy for colorectal liver matastasis-Surgical criteria for initially resectable and assessment toward conversion for unresectable cases-, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会, Jun. 2017.
85.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Liver resection for hepatocellular carcinoma of BCLC intermediate stage, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
86.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Shuichi Iwahashi, Tetsuya Ikemoto and Yuji Morine : 脳死肝移植を推進するための学生に対するDonor Actionの必要性について, 第35回日本肝移植研究会, Jun. 2017.
87.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : Tr1細胞とFoxp3調節性T細胞は消化器担癌状態におけるバイオマーカーとして有用である, 第26回日本癌病態治療研究会, Jun. 2017.
88.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : 肝葉切除術後に施行した膵切除術2例の経験, 第71回手術手技研究会, May 2017.
89.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 胃切除術における肥満の影響と治療成績改善への取り組み, 第117回日本外科学会定期学術集会, Apr. 2017.
90.	宮崎克己, Yu Saitou, Yuji Morine, Koichi Tsuneyama, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Toshiaki Yoshimoto, Atsushi Takata and Mitsuo Shimada : 限局性結節性過形成(FNH)術後に再発増殖し肝不全で死亡した一例, 第117回日本外科学会定期学術集会, Apr. 2017.
91.	Shogo Oota, Yuji Morine, Masato Yoshikawa, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto, Chie Takasu, Jun Higashijima and Mitsuo Shimada : 膵癌術後残膵再発に対する再切除導入効果の検証, 第117回日本外科学会定期学術集会, Apr. 2017.
92.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Yuji Morine, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 青色LED光は光受容体(opsin)を介し癌細胞増殖を抑制する, 第117回日本外科学会定期学術集会, Apr. 2017.
93.	Atsushi Takata, Jun Higashijima, Daichi Ishikawa, Masato Yoshikawa, Hideya Kashihara, Yu Saitou, Shuichi Iwahashi, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : 腸管吻合におけるKono-S吻合の有用性に関する検討, 第117回日本外科学会定期学術集会, Apr. 2017.
94.	Hiroki Teraoku, Mitsuo Shimada, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : 当科における膵全摘症例の検討-術後短期成績・長期予後の両面に着目して-, 第117回日本外科学会定期学術集会, Apr. 2017.
95.	Masato Yoshikawa, Rui Feng, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto, Chie Takasu, Jun Higashijima and Mitsuo Shimada : 肝細胞に対するROS/ ERK pathwayを介した赤色LED光の細胞増殖促進効果, 第117回日本外科学会定期学術集会, Apr. 2017.
96.	Daichi Ishikawa, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 大腸癌の発癌・腫瘍進展におけるmicroRNA-449aの意義, 第117回日本外科学会定期学術集会, Apr. 2017.
97.	川下陽一郎, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto, Hiroki Teraoku and Mitsuo Shimada : 肝内胆管癌におけるHSF1発現の意義, 第117回日本外科学会定期学術集会, Apr. 2017.
98.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : Cancer-associated fibroblastsを介した膵癌細胞におけるnab-paclitaxelの効果, 第117回日本外科学会定期学術集会, Apr. 2017.
99.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Masato Yoshikawa and Toshiaki Yoshimoto : Tr1細胞とFoxp3調節性T細胞による腫瘍免疫状態を反映する免疫学的バイオマーカー探索, 第117回日本外科学会定期学術集会, Apr. 2017.
100.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Jun Higashijima, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝切除シミュレーション・ナビゲーションを駆使した若手教育法の確立, 第117回日本外科学会定期学術集会, Apr. 2017.
101.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : 発光ダイオード(LED)の波長強度可変装置による肝細胞保護に関する研究, 第117回日本外科学会定期学術集会, Apr. 2017.
102.	Yu Saitou, Hisami Okumura, Yuji Morine, 平山明由, 梶浦大資, 多々納浩, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Toshiaki Yoshimoto, Atsushi Takata and Mitsuo Shimada : メタボローム解析を用いた肝切除後代謝物解析と肝再生因子の解明, 第117回日本外科学会定期学術集会, Apr. 2017.
103.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Jun Higashijima and Chie Takasu : 大腸癌肝転移における治療指針 - 原発・転移巣の腫瘍悪性度は相関しない?, 第117回日本外科学会定期学術集会, Apr. 2017.
104.	Yuji Morine, Hiroki Ishibashi, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Mitsuo Shimada : 「胆道拡張症，膵・胆管合流異常症の標準術式は?-小児外科および成人外科の立場から-」, 第117回日本外科学会定期学術集会, Apr. 2017.
105.	Yu Saitou, Yuji Morine, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝内胆管癌におけるHeat shock factor 1(HSF1)発現の意義, 第50回制癌剤適応研究会, Mar. 2017.
106.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 末梢血Tr1細胞とFoxp3陽性調節性T細胞は消化器担癌状態におけるバイオマーカーとして有用である, 第50回制癌剤適応研究会, Mar. 2017.
107.	Tetsuya Ikemoto, Mitsuo Shimada, Shuichi Iwahashi, Toshiaki Yoshimoto, Masato Yoshikawa, Yu Saitou, Yuji Morine and Satoru Imura : 8 ADSCによるInsulin-producing cell(IPCs)作成における効果的新規分化誘導方法に関する検討, 第44回日本膵・膵島移植研究会, Mar. 2017.
108.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Masato Yoshikawa : 肥満の胃切除術への影響と肥満患者における治療成績改善への取り組み, 第89回日本胃癌学会総会, Mar. 2017.
109.	Toshiaki Yoshimoto, Yu Saitou, Yuji Morine, Koichi Tsuneyama, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Atsushi Takata and Mitsuo Shimada : 限局性結節性過形成(FNH)術後に再発増殖し肝不全で死亡した一例-切除肝・病理解剖をふまえて-, 第66回日本消化器画像診断研究会, Feb. 2017.
110.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 膵腫瘍性病変におけるType1 regulatory T細胞の臨床的有用性の検討-Type1 regulatory T細胞は診断・再発予測バイオマーカーとして有用である-, 第254回徳島医学会学術集会, Feb. 2017.
111.	Yu Saitou, Yuji Morine, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝門部胆管癌超ハイリスク症例に対して根治術施行し術後管理, 第25回徳島外科術後管理研究会, Feb. 2017.
112.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Masato Yoshikawa : 胃切除術における肥満の影響と治療成績改善への取り組み, 第25回徳島外科術後管理研究会, Feb. 2017.
113.	Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Atsushi Takata, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : Long-term survivors of HCC using sorafenib, 2nd Eastern &Western Association Liver Tumors(EWALT), Jan. 2017.
114.	Masato Yoshikawa, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第15回日本肝がん分子標的治療研究会, Jan. 2017.
115.	Yu Saitou, Yuji Morine, 川下陽一郎, Masato Yoshikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝内胆管癌におけるHeat shock factor1(HSF1)発現の意義, 第15回日本肝がん分子標的治療研究会, Jan. 2017.
116.	Masato Yoshikawa, Rui Feng, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, Masaaki Nishi, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 肝細胞に対するROS/ERK pathwayを介した赤色LED光の細胞増殖促進効果, 第46回日本創傷治癒学会, Dec. 2016.
117.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 定型化と教育システムがもたらす安全な腹腔鏡下左葉切除, 第29回日本内視鏡外科学会総会, Dec. 2016.
118.	Masato Yoshikawa, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 若手医師による術前術中3D simulation画像を用いた腹腔鏡下手術の定型化, 第25回日本コンピュータ外科学会大会, Nov. 2016.
119.	Toshiaki Yoshimoto, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Chie Takasu : EOB-MRIを用いた新たな肝切除限界予測の可能性, 第78回日本臨床外科学会総会, Nov. 2016.
120.	Masato Yoshikawa, Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : 再発膵癌に対する再切除の有用性の検討, 第78回日本臨床外科学会総会, Nov. 2016.
121.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 当科における若手医師の腹腔鏡手術トレーニングの現状と効果, 第78回日本臨床外科学会総会, Nov. 2016.
122.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 若手外科医でも安全・確実に施行できる肝葉切除術, 第78回日本臨床外科学会総会, Nov. 2016.
123.	Yu Saitou, Yuji Morine, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 膵頭十二指腸切除術に対するModified de-rotation法を用いた`` Complete artery-f irst approach'', 第78回日本臨床外科学会総会, Nov. 2016.
124.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 膵全摘における人工膵臓の有用性における検討, 第78回日本臨床外科学会総会, Nov. 2016.
125.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa, Chie Takasu, Yusuke Arakawa and Jun Higashijima : 大腸癌切除不能多発肝転移に対する治療戦略, 第78回日本臨床外科学会総会, Nov. 2016.
126.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : グリソン一括による肝門処理のコツとピットフォール, 第78回日本臨床外科学会総会, Nov. 2016.
127.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Atsushi Takata, Toshiaki Yoshimoto, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Mitsuo Shimada : 当科における切除不能・再発進行膵癌に対する治療成績, 第54回日本癌治療学会学術集会, Oct. 2016.
128.	Daichi Ishikawa, 川下陽一郎, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : FBXW7発現は転移性肝癌における切除後再発予測因子となる, 第54回日本癌治療学会学術集会, Oct. 2016.
129.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 末梢血Tr1細胞とFoxp3調節性T細胞は担癌状態におけるバイオメーカーとして有用である, 第54回日本癌治療学会学術集会, Oct. 2016.
130.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa and Masato Yoshikawa : 消化器癌におけるヒストンアセチル化の抗腫瘍効果, 第75回日本癌学会学術集会, Oct. 2016.
131.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Toshiaki Yoshimoto : Tr1とFoxp3陽性調節性T細胞は担癌患者の腫瘍免疫に関する検討, 第75回日本癌学会学術集会, Oct. 2016.
132.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa and Daichi Ishikawa : 胃癌根治切除症例におけるPD1発現の意義, 第75回日本癌学会学術集会, Oct. 2016.
133.	Toshiaki Yoshimoto, Yu Saitou, Atsushi Takata, Masato Yoshikawa, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について, 第52回日本移植学会総会, Sep. 2016.
134.	Yu Saitou, Satoru Imura, Masato Yoshikawa, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 徳島におけるABO不適合生体肝移植の成績, 第52回日本移植学会総会, Sep. 2016.
135.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : 脂肪由来幹細胞によるInsulin-producing cell作成における新規分化誘導方法に関する検討, 第52回日本移植学会総会, Sep. 2016.
136.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 術前診断が困難であった肝偽リンパ腫の1例, 第65回日本消化器画像診断研究会, Sep. 2016.
137.	Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 若手医師による術前術中3D simulation画像を用いた腹腔鏡下手術の定型化, 第11回肝癌治療シミュレーション研究会, Sep. 2016.
138.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : RFA後肝細胞癌再発例はEMT誘導を介し腫瘍悪性度が増強する, 第35回Microwave Surgery研究会, Sep. 2016.
139.	Satoru Imura, Masato Yoshikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 担癌グリソン枝マイクロ波凝固による肝小範囲切除の工夫, 第35回Microwave Surgery研究会, Sep. 2016.
140.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第27回日本消化器癌発生学会総会, Sep. 2016.
141.	Daichi Ishikawa, Hiroki Teraoku, Atsushi Takata, Masato Yoshikawa, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 転移性肝癌における腫瘍悪性度制御因子としてのTHBS-1の役割, 第27回日本消化器癌発生学会総会, Sep. 2016.
142.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 消化器癌における末梢血Tr1細胞とFoxp3調節性T細胞の有用性の検討, 第27回日本消化器癌発生学会総会, Sep. 2016.
143.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku and Masato Yoshikawa : 肝内胆管癌の腫瘍悪性度評価と制御の可能性, 第27回日本消化器癌発生学会総会, Sep. 2016.
144.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 胆道癌術後肝内再発に対する肝切除導入効果の検証, 第91回中国四国外科学会総会/第21回中国四国内視鏡外科研究会, Sep. 2016.
145.	Chie Takasu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, 市井啓仁 and Mitsuo Shimada : 転写因子制御による肝虚血再灌流障害の新たな治療法の開発., 第253回徳島医学会学術集会, Jul. 2016.
146.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : Boot Camp in Tokushima University., 第71回日本消化器外科学会総会, Jul. 2016.
147.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : The analysis in non-tumor liver tissue to prevent the recurrence after curative treatment of hepatocellular carcinoma., 第71回日本消化器外科学会総会, Jul. 2016.
148.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Hiroki Teraoku : A new strategy forachieving effective islet transplantation with adipose tissue derved stem cells., 第71回日本消化器外科学会総会, Jul. 2016.
149.	Yuji Morine, Mitsuo Shimada, Hiroki Ishibashi, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa and Masato Yoshikawa : 全国集計からみた膵・胆管合流異常症の臨床摘特徴と術式選択の現状., 第71回日本消化器外科学会総会, Jul. 2016.
150.	Masato Yoshikawa, Yu Saitou, Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : ABO不適合生体肝移植後にCMV感染治療に難渋した一例., 第34回日本肝移植研究会, Jul. 2016.
151.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : NO阻害と転写活性制御からの虚血再灌流障害., 第34回日本肝移植研究会, Jul. 2016.
152.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について., 第34回日本肝移植研究会, Jul. 2016.
153.	Yu Saitou, Sonoko Yasui, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝硬変合併肝切除症例における栄養・免疫状態の特徴, 第52回日本肝癌研究会, Jul. 2016.
154.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa and Atsushi Takata : 症例, 第52回日本肝癌研究会, Jul. 2016.
155.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Intermediate stageの肝癌に対する肝切除は有効か?, 第52回日本肝癌研究会, Jul. 2016.
156.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Masato Yoshikawa : 肝内胆管癌における発生部位別悪性度., 第52回日本肝癌研究会, Jul. 2016.
157.	Toshiaki Yoshimoto, Kouzou Yoshikawa, 松本規子, Atsushi Takata, Yu Saitou, Masato Yoshikawa, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Daichi Ishikawa, Shuichi Iwahashi and Mitsuo Shimada : 青色LED光のヒト癌細胞株に対する効果., 第105回日本消化器病学会四国支部例会, Jun. 2016.
158.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Atsushi Takata, Toshiaki Yoshimoto, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Mitsuo Shimada : 切除不能・再発進行膵癌に対する治療成績., 第105回日本消化器病学会四国支部例会, Jun. 2016.
159.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : ノンテクニカルスキルを含めた総合手術技能評価法の開発., 第105回日本消化器病学会四国支部例会, Jun. 2016.
160.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yusuke Arakawa, Shuichi Iwahashi, Daichi Ishikawa, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : HCCに対して初回RFA治療早期にリンパ節再発をきたし外科的切除を施行した症例., 第41回日本外科系連合学会学術集会, Jun. 2016.
161.	Yu Saitou, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : PDに対するModified de-rotationを用いた``Complate artery-firstn approach''., 第41回日本外科系連合学会学術集会, Jun. 2016.
162.	Toshiaki Yoshimoto, C Enkbold, Atsushi Takata, Masato Yoshikawa, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 肝内胆管癌における細胞周期調節因子Fbxw7発現低下の臨床病理学的意義., 第14回日本肝がん分子標的治療研究会, Jun. 2016.
163.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : RFA後肝細胞癌再発例はEMT誘導を介し腫瘍悪性度が増強する., 第14回日本肝がん分子標的治療研究会, Jun. 2016.
164.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : EOB-MRIを用いた機能的肝容積による新たな肝切除基準., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
165.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Masato Yoshikawa : Tr1細胞とFoxp3調節性T細胞による膵嚢胞性疾患に関する正確な免疫学的指標探索に関する研究., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
166.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 胆道癌術後肝内再発に対する肝切除導入効果の検証., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
167.	Masato Yoshikawa, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 当科における胆道再建における肝管空腸吻合法の工夫., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
168.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Chie Takasu, Jun Higashijima, 川下陽一郎, Atsushi Takata, Toshiaki Yoshimoto, Satoru Imura and Mitsuo Shimada : 大腸癌肝転移肝切除症例におけるThrombospondin1(THBS)発現の意義とその分子メカニズムの検討., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
169.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa and Jun Higashijima : 大腸癌多発肝転移に対する長期生存を目指した治療戦略., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
170.	Masato Yoshikawa, Yuji Morine and Mitsuo Shimada : 肝細胞癌におけるNEK2発現による腫瘍悪性度評価., 第52回日本肝臓学会総会, May 2016.
171.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 徳島におけるABO不適合生体肝移植症例の成績., 第42回日本急性肝不全研究会, May 2016.
172.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 転移性肝癌における腫瘍悪性度制御因子としてのHIF-1の役割., 第102回日本消化器病学会総会, Apr. 2016.
173.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto, Atsushi Takata and Chie Takasu : EOB-MRIを用いた新たな肝切除基準の可能性, 第102回日本消化器病学会総会, Apr. 2016.
174.	Kouzou Yoshikawa, Mitsuo Shimada, Toshihiro Nakao, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : 直腸癌術前CRT症例におけるKi-67, Survivin発現の意義, 第102回日本消化器病学会総会, Apr. 2016.
175.	Shoko Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 急速な進展を来したラブドイド様退形成性癌の一例., 第116回日本外科学会定期学術集会, Apr. 2016.
176.	関勇輔, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : RFA術後にリンパ節再発をきたし外科切除を施行した肝細胞癌の1例 -RFA術後再発におけるEMT誘導を介した悪性度獲得について-., 第116回日本外科学会定期学術集会, Apr. 2016.
177.	Atsushi Takata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Chie Takasu : 腸管修復および癌幹細胞におけるSonic hedgehogの役割., 第116回日本外科学会定期学術集会, Apr. 2016.
178.	川下陽一郎, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Higashijima, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto and Hirohisa Ogawa : 転移性肝癌におけるFbxw7低発現は再発予測因子である., 第116回日本外科学会定期学術集会, Apr. 2016.
179.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Takuya Tokunaga, Hiroki Teraoku, Masato Yoshikawa, Atsushi Takata and Mitsuo Shimada : 直腸癌術前CRT症例におけるKi-67，Survivin発現の意義, 第116回日本外科学会定期学術集会, Apr. 2016.
180.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第116回日本外科学会定期学術集会, Apr. 2016.
181.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 転移性肝癌における腫瘍悪性度制御因子としてのThrombospondin-1(THBS-1)の役割- 第2報 THBS-1制御メカニズムについて -, 第116回日本外科学会定期学術集会, Apr. 2016.
182.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : HDAC阻害剤は脂肪由来幹細胞からインスリン分泌細胞への分化誘導を促進する., 第116回日本外科学会定期学術集会, Apr. 2016.
183.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku and Masato Yoshikawa : 肝内胆管癌に対する至適術式と集学的治療., 第116回日本外科学会定期学術集会, Apr. 2016.
184.	布村俊幸, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Hiroki Teraoku, Masato Yoshikawa and Toshiaki Yoshimoto : 切除不能転移性肝癌を有する透析患者にFOLFOXIRI+Bevを施行しconversionが得られる1例., 第116回日本外科学会定期学術集会, Apr. 2016.
185.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Masato Yoshikawa and Toshiaki Yoshimoto : 膵癌細胞におけるResveratrolのShh pathwayを介した細胞増殖抑制効果, 第116回日本外科学会定期学術集会, Apr. 2016.
186.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : 進行大腸癌に対する新たな予後予測因子の検討., 第116回日本外科学会定期学術集会, Apr. 2016.
187.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Toshiaki Yoshimoto, Atsushi Takata and Masato Yoshikawa : 青色LED光は癌細胞増殖を抑制する., 第116回日本外科学会定期学術集会, Apr. 2016.
188.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : 高齢者胃癌症例に対するリンパ節郭清範囲縮小の予後に及ぼす影響, 第88回日本胃癌学会総会, Mar. 2016.
189.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : 脂肪由来幹細胞による膵島移植・膵島再生に関する新たな戦略, 第43回日本膵・膵島移植研究会, Mar. 2016.
190.	Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 36.3mm細径鉗子を用いたreduced port Lap-Cに関する検討, 第30回四国内視鏡外科研究会, Feb. 2016.
191.	Masato Yoshikawa : 肝内胆管癌との鑑別が困難であった原発性放線菌症の一例, 第63回日本消化器画像診断研究会, Sep. 2015.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Development of tissue engineering method using bioabsorbable scaffolds and new intestinal regeneration method using red LED (Project/Area Number: 19K24014 )
Search by Researcher Number (60737097)

Designated Assistant Professor : Yoshikawa, Masato

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)